AR
NVCR icon

Advisory Research’s NovoCure NVCR Stock Holding History

Advisory Research’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,893
Closed -$405K – 414
2022
Q1 		$405K Buy
4,893
+1,835
+60% +$135K 0.03% 272
2021
Q4 		$230K Sell
3,058
-8,036
-72% -$807K 0.02% 296
2021
Q3 		$1.29M Sell
11,094
-7,046
-39% -$1.07M 0.08% 169
2021
Q2 		$4.02M Sell
18,140
-657
-3% -$128K 0.27% 96
2021
Q1 		$2.48M Sell
18,797
-6,812
-27% -$1.08M 0.18% 115
2020
Q4 		$4.43M Sell
25,609
-16,347
-39% -$2.24M 0.32% 82
2020
Q3 		$4.67M Buy
41,956
+8,584
+26% +$686K 0.46% 69
2020
Q2 		$1.98M Sell
33,372
-3,934
-11% -$259K 0.18% 111
2020
Q1 		$2.51M Sell
37,306
-3,312
-8% -$262K 0.17% 74
2019
Q4 		$3.42M Buy
40,618
+15,094
+59% +$1.22M 0.16% 84
2019
Q3 		$1.91M Sell
25,524
-49,237
-66% -$3.94M 0.09% 128
2019
Q2 		$4.73M Buy
74,761
+12,344
+20% +$625K 0.09% 127
2019
Q1 		$3.01M Sell
62,417
-3,741
-6% -$180K 0.06% 153
2018
Q4 		$2.21M Sell
66,158
-27,314
-29% -$999K 0.05% 178
2018
Q3 		$4.9M Sell
93,472
-41,238
-31% -$1.64M 0.08% 140
2018
Q2 		$4.22M Buy
134,710
+18,400
+16% +$512K 0.07% 161
2018
Q1 		$2.54M Buy
116,310
+12,501
+12% +$269K 0.05% 195
2017
Q4 		$2.1M Sell
103,809
-7,500
-7% -$144K 0.03% 216
2017
Q3 		$2.21M Buy
111,309
+30,241
+37% +$594K 0.04% 208
2017
Q2 		$1.4M Buy
+81,068
New +$1.05M 0.02% 275

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisory Research's NVCR Position: Q2 2022 in Review

Advisory Research sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 4,893 shares — an estimated $405K sold.

Advisory Research first reported a position in NVCR in Q2 2017 and held it in 20 quarters. The position peaked at $4.9M in Q3 2018. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

  • Advisory Research reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
  • Advisory Research sold 4,893 NovoCure shares in Q2 2022, an estimated $405K.
  • Advisory Research first reported a position in NovoCure in Q2 2017 and held it in 20 quarters.
  • Advisory Research's NovoCure position peaked at $4.9M in Q3 2018.
  • 316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Advisory Research's 13F filing for Q2 2022, filed 15 Aug 2022.